利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.043 秒)

    T cell epitopes of ryegrass pollen allergen
    1.
    发明授权
    T cell epitopes of ryegrass pollen allergen 失效
    黑麦草花粉过敏原的T细胞表位

    公开(公告)号：US07112333B1

    公开(公告)日：2006-09-26

    申请号：US08737904

    申请日：1994-08-05

    申请人： Irwin J. Griffith ,  Mei-Chang Kuo ,  Mohammad Luqman

    发明人： Irwin J. Griffith ,  Mei-Chang Kuo ,  Mohammad Luqman

    IPC分类号： A61K38/04 ,  A61K38/10 ,  C07K7/00 ,  C07K7/06

    CPC分类号： C07K7/08 ,  A61K38/00 ,  Y10S514/885 ,  Y10S530/868

    摘要： The present invention provides isolated peptides of Lol p V, a major protein allergen of the species Lolium perenne. Therapeutic peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of a protein allergen of Lol p V. Diagnostic peptides within the scope of the invention bind IgE. The invention also provides modified peptides having similar or enhanced therapeutic properties or other desirable properties as the corresponding, naturally-occurring allergen or portion thereof. The invention further provides nucleic acid sequences coding for peptides of the invention. Use of the therapeutic compositions comprising one or more peptides of the invention in the manufacture of medicaments for treating sensitivity to Lol p V or an allergen immunologically related to Lol p V, or for general ryegrass sensitivity in an individual, is also provided. The invention also provides nucleic acid sequence coding for Dac g V protein allergen as well as the amino acid sequence of Dac g V protein allergen.

    摘要翻译： 本发明提供了Lol p V的孤立肽，Lol p V是白僵菌物种的主要蛋白质过敏原。 本发明范围内的治疗肽包含至少一个T细胞表位，或优选至少两个Lol p V蛋白变应原的T细胞表位。本发明范围内的诊断肽结合IgE。 本发明还提供具有与相应的天然存在的变应原或其部分相似或增强的治疗性质或其它所需性质的修饰肽。 本发明还提供了编码本发明的肽的核酸序列。 还提供了包含本发明的一种或多种肽的治疗组合物在制备用于治疗对Lol p V的敏感性的药物或与Lol p V免疫相关的变应原的治疗组合物或在个体中的一般黑麦草敏感性的用途。 本发明还提供编码Dac g V蛋白变应原的核酸序列以及Dac g V蛋白变应原的氨基酸序列。

    T cell epitopes of ryegrass pollen allergen
    2.
    发明授权
    T cell epitopes of ryegrass pollen allergen 失效
    黑麦草花粉过敏原的T细胞表位

    公开(公告)号：US5710126A

    公开(公告)日：1998-01-20

    申请号：US440861

    申请日：1995-05-15

    申请人： Irwin J. Griffith ,  Mei-chang Kuo ,  Mohammad Luqman

    发明人： Irwin J. Griffith ,  Mei-chang Kuo ,  Mohammad Luqman

    IPC分类号： A61K38/00 ,  C07K14/415 ,  C07K16/16 ,  A61K38/10 ,  A61K38/16 ,  A61K39/36

    CPC分类号： C07K14/415 ,  C07K16/16 ,  A61K38/00

    摘要： The present invention provides isolated peptides of Lol p V, a major protein allergen of the species Lolium perenne. Therapeutic peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of a protein allergen of Lol p V. Diagnostic peptides within the scope of the invention bind IgE. The invention also provides modified peptides having similar or enhanced therapeutic properties as the corresponding, naturally-occurring allergen or portion thereof, but having reduced side effects. The invention further provides nucleic acid sequences coding for peptides of the invention. Methods of treatment or diagnosis of sensitivity to Lol p V or an allergen immunologically related to Lol p V in an individual. Therapeutic compositions comprising one or more peptides of the invention are also provided.

    摘要翻译： 本发明提供了Lol p V的孤立肽，Lol p V是白僵菌物种的主要蛋白质过敏原。 本发明范围内的治疗肽包含至少一个T细胞表位，或优选至少两个Lol p V蛋白变应原的T细胞表位。本发明范围内的诊断肽结合IgE。 本发明还提供了与相应的天然存在的变应原或其部分具有相似或增强的治疗性质但具有减少的副作用的修饰肽。 本发明还提供了编码本发明的肽的核酸序列。 治疗或诊断对Lol p V的敏感性或与个体中Lol p V免疫相关的变应原的方法。 还提供了包含本发明的一种或多种肽的治疗组合物。

    Use of Antagonist Anti-Cd40 Monoclonal Antibodies for Treatment of Multiple Myeloma
    3.
    发明申请
    Use of Antagonist Anti-Cd40 Monoclonal Antibodies for Treatment of Multiple Myeloma 审中-公开
    使用拮抗剂抗Cd40单克隆抗体治疗多发性骨髓瘤

    公开(公告)号：US20070218060A1

    公开(公告)日：2007-09-20

    申请号：US10578387

    申请日：2004-11-04

    申请人： Li Long ,  Mohammad Luqman ,  Asha Yabannavar ,  Isabel Zaror

    发明人： Li Long ,  Mohammad Luqman ,  Asha Yabannavar ,  Isabel Zaror

    IPC分类号： C07K16/00

    CPC分类号： C07K16/2878 ,  A61K38/2013 ,  A61K39/39558 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  A61K2300/00

    摘要： Methods of therapy for treating a subject for multiple myeloma are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40 expressing multiple myeloma cells.

    摘要翻译： 提供了治疗多发性骨髓瘤受试者的治疗方法。 所述方法包括向有需要的患者施用治疗有效量的拮抗性抗CD40抗体或其抗原结合片段。 拮抗性抗CD40抗体或其抗原结合片段没有显着的激动剂活性，但当抗体结合表达人CD40的细胞上的CD40抗原时，其表现出拮抗剂活性。 抗体抗体或其抗原结合片段的拮抗作用有利地抑制人CD40表达多发性骨髓瘤细胞的增殖和/或分化。

    USES OF ANTI-CD40 ANTIBODIES
    4.
    发明申请
    USES OF ANTI-CD40 ANTIBODIES 审中-公开
    抗CD40抗体的使用

    公开(公告)号：US20090202531A1

    公开(公告)日：2009-08-13

    申请号：US12092256

    申请日：2006-11-01

    申请人： Sharon Lea Aukerman ,  Mohammad Luqman

    发明人： Sharon Lea Aukerman ,  Mohammad Luqman

    IPC分类号： A61K39/395 ,  C12Q1/68

    CPC分类号： C07K16/2878 ,  C07K16/2887 ,  C07K2317/732 ,  C07K2317/77

    摘要： Methods for treating a human patient for an inflammatory or autoimmune disease that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for FcγRIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for FcγRIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with an inflammatory or autoimmune disease that is treatable with an anti-CD40 antibody and which is non-responsive or refractory to treatment with rituximab (Rituxan®), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having an inflammatory or autoimmune disease that is non-responsive or refractory to treatment with rituximab (Rituxan®), are also provided. The methods of the present invention find use in treatment of inflammatory diseases and autoimmune diseases that are associated with CD40-expressing cells. These methods are particularly advantageous with respect to inflammatory diseases and autoimmune diseases that are associated with cells expressing both CD40 and CD20, as the methods enable the treatment of patients having an inflammatory or autoimmune disease that is non-responsive or refractory to therapy with other therapeutic agents such as anti-CD20 antibodies.

    摘要翻译： 提供了用于治疗患有与表达CD40的细胞相关的炎性或自身免疫性疾病的人类患者的方法，其中人类患者对于FcgammaRIIIa-158F（基因型V / F或F / F）是杂合的或纯合的。 还提供了抑制对FcgammaRIIIa-158F（基因型V / F或F / F）是杂合的或纯合的人类患者中B细胞的抗体产生的方法。 所述方法包括向人类患者施用治疗或预防有效量的抗CD40抗体。 用于鉴定具有可用抗CD40抗体治疗并且对利妥昔单抗治疗无反应或难治性的炎性或自身免疫性疾病的人类患者的方法和试剂盒以及用于选择的方法和试剂盒 还提供了用于治疗具有对利妥昔单抗治疗无反应或难治的炎性或自身免疫性疾病的人类患者的抗体疗法（Rituxan）。 本发明的方法可用于治疗与CD40表达细胞相关的炎性疾病和自身免疫性疾病。 这些方法对于与表达CD40和CD20的细胞相关的炎性疾病和自身免疫性疾病是特别有利的，因为该方法能够治疗患有对其他治疗无效或难治的炎性或自身免疫性疾病的患者 药物如抗CD20抗体。

    Methods for Diagnosis and Treatment of Diseases Having an Autoimmune and/or Inflammatory Component
    6.
    发明申请
    Methods for Diagnosis and Treatment of Diseases Having an Autoimmune and/or Inflammatory Component 有权
    具有自身免疫和/或炎症成分的疾病的诊断和治疗方法

    公开(公告)号：US20080274118A1

    公开(公告)日：2008-11-06

    申请号：US11914710

    申请日：2006-05-18

    申请人： Sharon Lea Aukerman ,  Bahija Jallal ,  Mohammad Luqman

    发明人： Sharon Lea Aukerman ,  Bahija Jallal ,  Mohammad Luqman

    IPC分类号： A61K39/395 ,  G01N33/567 ,  A61P1/00 ,  A61P3/00 ,  A61P19/00 ,  A61P29/00 ,  A61P37/00 ,  A61P25/00

    CPC分类号： G01N33/564 ,  G01N33/5091 ,  G01N33/533 ,  G01N33/57484 ,  G01N33/582 ,  G01N2800/24 ,  G01N2800/52

    摘要： Methods for identifying subjects having an inflammatory disease and/or autoimmune disease that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.

    摘要翻译： 提供了用于鉴定将受益于调节CD40L介导的CD40信号传导的抗CD40治疗剂的炎性疾病和/或自身免疫性疾病的受试者的方法。 所述方法包括使用细胞凋亡，细胞增殖和存活的生物标志物，以及CD40信号通路来监测对一种或多种调节CD40表达细胞上的CD40信号传导的抗CD40治疗剂的离体反应。 离体预后测定可以单独使用或与其他预后测定结合使用，以鉴定将受益于抗CD40治疗剂治疗的候选受试者。 本发明的方法还包括使用这些生物标志物来监测用抗CD40治疗剂治疗的体内功效。

    Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject having an inflammatory or autoimmune disease
    8.
    发明授权
    Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject having an inflammatory or autoimmune disease 有权
    监测抗CD40抗体在治疗具有炎性或自身免疫疾病的受试者中的功效的方法

    公开(公告)号：US08333970B2

    公开(公告)日：2012-12-18

    申请号：US11914710

    申请日：2006-05-18

    申请人： Sharon Lea Aukerman ,  Bahija Jallal ,  Mohammad Luqman

    发明人： Sharon Lea Aukerman ,  Bahija Jallal ,  Mohammad Luqman

    IPC分类号： A61K39/395 ,  C12Q1/00 ,  C12Q1/68 ,  G01N33/53

    CPC分类号： G01N33/564 ,  G01N33/5091 ,  G01N33/533 ,  G01N33/57484 ,  G01N33/582 ,  G01N2800/24 ,  G01N2800/52

    摘要： Methods for identifying subjects having an inflammatory disease and/or autoimmune disease that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.

    摘要翻译： 提供了用于鉴定将受益于调节CD40L介导的CD40信号传导的抗CD40治疗剂的炎性疾病和/或自身免疫性疾病的受试者的方法。 所述方法包括使用细胞凋亡，细胞增殖和存活的生物标志物，以及CD40信号通路来监测对一种或多种调节CD40表达细胞上的CD40信号传导的抗CD40治疗剂的离体反应。 离体预后测定可以单独使用或与其他预后测定结合使用，以鉴定将受益于抗CD40治疗剂治疗的候选受试者。 本发明的方法还包括使用这些生物标志物来监测用抗CD40治疗剂治疗的体内功效。

    Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
    9.
    发明申请
    Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia 审中-公开
    使用拮抗剂抗CD40抗体治疗慢性淋巴细胞性白血病

    公开(公告)号：US20070110754A1

    公开(公告)日：2007-05-17

    申请号：US10577642

    申请日：2004-11-04

    申请人： Li Long ,  Mohammad Luqman ,  Asha Yabannavar ,  Isabet Zaror ,  Sharon Aukerman

    发明人： Li Long ,  Mohammad Luqman ,  Asha Yabannavar ,  Isabet Zaror ,  Sharon Aukerman

    IPC分类号： A61K39/395 ,  C07K16/30

    CPC分类号： C07K16/2878 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

    摘要： Methods of therapy for treating a subject for chronic lymphocytic leukemia are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CN40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing chronic lymphocytic leukemia cells.

    摘要翻译： 提供了治疗慢性淋巴细胞性白血病受试者的治疗方法。 所述方法包括向有需要的患者施用治疗有效量的拮抗性抗CN40抗体或其抗原结合片段。 拮抗性抗CD40抗体或其抗原结合片段没有显着的激动剂活性，但当抗体结合表达人CD40的细胞上的CD40抗原时，其表现出拮抗剂活性。 抗CD40抗体或其抗原结合片段的拮抗作用有益地抑制人CD40表达慢性淋巴细胞白血病细胞的增殖和/或分化。

    Treatment of cancer or pre-malignant conditions using anti-CD40 antibodies
    10.
    发明授权
    Treatment of cancer or pre-malignant conditions using anti-CD40 antibodies 有权
    使用抗CD40抗体治疗癌症或恶性前病症

    公开(公告)号：US08926979B2

    公开(公告)日：2015-01-06

    申请号：US12092247

    申请日：2006-11-01

    申请人： Sharon Lea Aukerman ,  Mohammad Luqman

    发明人： Sharon Lea Aukerman ,  Mohammad Luqman

    IPC分类号： A61K39/395 ,  C07K16/28 ,  A61K39/00

    CPC分类号： C12Q1/6881 ,  A61K2039/505 ,  C07K16/2878 ,  C07K2317/732 ,  C12Q2600/106 ,  C12Q2600/158

    摘要： Methods for treating a human patient for a cancer or pre-malignant condition that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for FcγRIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for FcγRIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with a cancer or pre-malignant condition that is treatable with an anti-CD40 antibody and which is refractory to treatment with rituximab (Rituxan®), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having a cancer or pre-malignant condition that is refractory to treatment with rituximab (Rituxan®), are also provided. The methods of the present invention find use in treatment of cancers and pre-malignant conditions that are associated with CD40-expressing cells. These methods are particularly advantageous with respect to cancers and pre-malignant conditions that are associated with cells expressing both CD40 and CD20, as the methods enable the treatment of patients having a cancer or pre-malignant condition that is refractory to therapy with other oncotherapeutic agents such as anti-CD20 antibodies.

    摘要翻译： 提供了用于治疗人类患者与CD40表达细胞相关的癌症或恶性前病症的方法，其中人类患者是FcγRIIIa-158F（基因型V / F或F / F）是杂合的或纯合的。 还提供了抑制对FcγRIIIa-158F（基因型V / F或F / F）是杂合的或纯合的人类患者中B细胞的抗体产生的方法。 所述方法包括向人类患者施用治疗或预防有效量的抗CD40抗体。 用于鉴定具有可用抗CD40抗体治疗且难以用利妥昔单抗治疗的癌症或恶性前病症的人类患者的方法和试剂盒，以及用于选择抗体治疗的方法和试剂盒 还提供了治疗患有利妥昔单抗治疗难治的癌症或恶性前病症的人类患者。 本发明的方法可用于治疗与CD40表达细胞相关的癌症和恶性前恶性病症。 这些方法对于与表达CD40和CD20的细胞相关的癌症和恶性前病症是特别有利的，因为该方法能够治疗具有与其它治疗剂治疗难治的癌症或恶变前病症的患者 如抗CD20抗体。